273 related articles for article (PubMed ID: 19914392)
1. Transcription factor Stat5a/b as a therapeutic target protein for prostate cancer.
Liao Z; Lutz J; Nevalainen MT
Int J Biochem Cell Biol; 2010 Feb; 42(2):186-92. PubMed ID: 19914392
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer.
Gu L; Liao Z; Hoang DT; Dagvadorj A; Gupta S; Blackmon S; Ellsworth E; Talati P; Leiby B; Zinda M; Lallas CD; Trabulsi EJ; McCue P; Gomella L; Huszar D; Nevalainen MT
Clin Cancer Res; 2013 Oct; 19(20):5658-74. PubMed ID: 23942095
[TBL] [Abstract][Full Text] [Related]
3. Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia.
Liao Z; Gu L; Vergalli J; Mariani SA; De Dominici M; Lokareddy RK; Dagvadorj A; Purushottamachar P; McCue PA; Trabulsi E; Lallas CD; Gupta S; Ellsworth E; Blackmon S; Ertel A; Fortina P; Leiby B; Xia G; Rui H; Hoang DT; Gomella LG; Cingolani G; Njar V; Pattabiraman N; Calabretta B; Nevalainen MT
Mol Cancer Ther; 2015 Aug; 14(8):1777-93. PubMed ID: 26026053
[TBL] [Abstract][Full Text] [Related]
4. N-terminal truncation of Stat5a/b circumvents PIAS3-mediated transcriptional inhibition of Stat5 in prostate cancer cells.
Dagvadorj A; Tan SH; Liao Z; Xie J; Nurmi M; Alanen K; Rui H; Mirtti T; Nevalainen MT
Int J Biochem Cell Biol; 2010 Dec; 42(12):2037-46. PubMed ID: 20854925
[TBL] [Abstract][Full Text] [Related]
5. Signal transducer and activator of transcription 5A/B in prostate and breast cancers.
Tan SH; Nevalainen MT
Endocr Relat Cancer; 2008 Jun; 15(2):367-90. PubMed ID: 18508994
[TBL] [Abstract][Full Text] [Related]
6. Transcription factor signal transducer and activator of transcription 5 promotes growth of human prostate cancer cells in vivo.
Dagvadorj A; Kirken RA; Leiby B; Karras J; Nevalainen MT
Clin Cancer Res; 2008 Mar; 14(5):1317-24. PubMed ID: 18316550
[TBL] [Abstract][Full Text] [Related]
7. Signal transducer and activator of transcription 5a/b: biomarker and therapeutic target in prostate and breast cancer.
Koptyra M; Gupta S; Talati P; Nevalainen MT
Int J Biochem Cell Biol; 2011 Oct; 43(10):1417-21. PubMed ID: 21704724
[TBL] [Abstract][Full Text] [Related]
8. Hypoxic tumor kinase signaling mediated by STAT5A in development of castration-resistant prostate cancer.
Røe K; Bratland Å; Vlatkovic L; Ragnum HB; Saelen MG; Olsen DR; Marignol L; Ree AH
PLoS One; 2013; 8(5):e63723. PubMed ID: 23675504
[TBL] [Abstract][Full Text] [Related]
9. Activating mutation (V617F) in the tyrosine kinase JAK2 is absent in locally-confined or castration-resistant prostate cancer.
Gu L; Zhu XH; Visakorpi T; Alanen K; Mirtti T; Edmonston TB; Nevalainen MT
Anal Cell Pathol (Amst); 2010; 33(2):55-9. PubMed ID: 20966544
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.
Hoang DT; Iczkowski KA; Kilari D; See W; Nevalainen MT
Oncotarget; 2017 Jan; 8(2):3724-3745. PubMed ID: 27741508
[TBL] [Abstract][Full Text] [Related]
11. STAT5A/B Blockade Sensitizes Prostate Cancer to Radiation through Inhibition of RAD51 and DNA Repair.
Maranto C; Udhane V; Hoang DT; Gu L; Alexeev V; Malas K; Cardenas K; Brody JR; Rodeck U; Bergom C; Iczkowski KA; Jacobsohn K; See W; Schmitt SM; Nevalainen MT
Clin Cancer Res; 2018 Apr; 24(8):1917-1931. PubMed ID: 29483142
[No Abstract] [Full Text] [Related]
12. Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells.
Tan SH; Dagvadorj A; Shen F; Gu L; Liao Z; Abdulghani J; Zhang Y; Gelmann EP; Zellweger T; Culig Z; Visakorpi T; Bubendorf L; Kirken RA; Karras J; Nevalainen MT
Cancer Res; 2008 Jan; 68(1):236-48. PubMed ID: 18172316
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer.
Hoang DT; Gu L; Liao Z; Shen F; Talati PG; Koptyra M; Tan SH; Ellsworth E; Gupta S; Montie H; Dagvadorj A; Savolainen S; Leiby B; Mirtti T; Merry DE; Nevalainen MT
Mol Cancer Ther; 2015 Mar; 14(3):713-26. PubMed ID: 25552366
[TBL] [Abstract][Full Text] [Related]
14. Transcription factor Stat3 stimulates metastatic behavior of human prostate cancer cells in vivo, whereas Stat5b has a preferential role in the promotion of prostate cancer cell viability and tumor growth.
Gu L; Dagvadorj A; Lutz J; Leiby B; Bonuccelli G; Lisanti MP; Addya S; Fortina P; Dasgupta A; Hyslop T; Bubendorf L; Nevalainen MT
Am J Pathol; 2010 Apr; 176(4):1959-72. PubMed ID: 20167868
[TBL] [Abstract][Full Text] [Related]
15. Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway.
Dagvadorj A; Collins S; Jomain JB; Abdulghani J; Karras J; Zellweger T; Li H; Nurmi M; Alanen K; Mirtti T; Visakorpi T; Bubendorf L; Goffin V; Nevalainen MT
Endocrinology; 2007 Jul; 148(7):3089-101. PubMed ID: 17412813
[TBL] [Abstract][Full Text] [Related]
16. SOCS2 mediates the cross talk between androgen and growth hormone signaling in prostate cancer.
Iglesias-Gato D; Chuan YC; Wikström P; Augsten S; Jiang N; Niu Y; Seipel A; Danneman D; Vermeij M; Fernandez-Perez L; Jenster G; Egevad L; Norstedt G; Flores-Morales A
Carcinogenesis; 2014 Jan; 35(1):24-33. PubMed ID: 24031028
[TBL] [Abstract][Full Text] [Related]
17. Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate Cancer.
Talati PG; Gu L; Ellsworth EM; Girondo MA; Trerotola M; Hoang DT; Leiby B; Dagvadorj A; McCue PA; Lallas CD; Trabulsi EJ; Gomella L; Aplin AE; Languino L; Fatatis A; Rui H; Nevalainen MT
Am J Pathol; 2015 Sep; 185(9):2505-22. PubMed ID: 26362718
[TBL] [Abstract][Full Text] [Related]
18. Recent progress in the development of protein-protein interaction inhibitors targeting androgen receptor-coactivator binding in prostate cancer.
Biron E; Bédard F
J Steroid Biochem Mol Biol; 2016 Jul; 161():36-44. PubMed ID: 26196120
[TBL] [Abstract][Full Text] [Related]
19. Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer.
Erb HHH; Bodenbender J; Handle F; Diehl T; Donix L; Tsaur I; Gleave M; Haferkamp A; Huber J; Fuessel S; Juengel E; Culig Z; Thomas C
PLoS One; 2020; 15(8):e0237248. PubMed ID: 32790723
[TBL] [Abstract][Full Text] [Related]
20. Growth factor and signaling pathways and their relevance to prostate cancer therapeutics.
Wozney JL; Antonarakis ES
Cancer Metastasis Rev; 2014 Sep; 33(2-3):581-94. PubMed ID: 24402967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
